TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10098571

Group type: EXPERIMENTAL
Intervention: Brochure
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Lecture/Discussion
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Active Decision Support
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: PDS Tools (all formats)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: More Intensive Interventions
Number of subjects: 248
Study: 9345431

Group type: EXPERIMENTAL
Intervention: Caucasian MS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caucasian MS patients with prominent optic neuritis (PON)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 1817628

Group type: COMPARATOR
Intervention: Morphine 3 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Clonidine 75 micrograms
Number of subjects: 28

Group type: COMPARATOR
Intervention: Morphine 3 mg plus Clonidine 75 micrograms
Number of subjects: 28
Study: 6115999

Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 23582

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 23582

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23582
Study: 31842036

Group type: EXPERIMENTAL
Intervention: Topical 1.5% Azithromycin (AZ) administered as a unit dose
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no topical AZ)
Number of subjects: 85
Study: 31823650

Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT) 15 g extract granule daily for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT)
Number of subjects: 0
Study: 28292739

Group type: EXPERIMENTAL
Intervention: Website with product-specific information
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Website without product-specific information
Number of subjects: 672

Group type: COMPARATOR
Intervention: Control group (no access to the website)
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Website use
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Evaluation of the website
Number of subjects: 672
Study: 25944023

Group type: EXPERIMENTAL
Intervention: Smoking-reduction intervention (SRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise- and diet-advice arm (EDA)
Number of subjects: 0
Study: 23359067

Group type: EXPERIMENTAL
Intervention: HM10460A 45 μg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HM10460A 135 μg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HM10460A 350 μg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21323679

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (peak breath alcohol concentration of 0.11 ± 0.01 g%)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 17728695

Group type: EXPERIMENTAL
Intervention: Enteral glutamine, 0.65 g kg(‐1) daily for 7 days
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no glutamine)
Number of subjects: 76
Study: 16720935

Group type: EXPERIMENTAL
Intervention: Whole-body-vibration (WBV) treatment, 5 series of 60 seconds each
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no WBV treatment)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Whole-body-vibration (WBV) treatment (cross-over design)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Whole-body-vibration (WBV) treatment
Number of subjects: 68
Study: 15533869

Group type: EXPERIMENTAL
Intervention: Baseline NT-proBNP levels >250 ng/L
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: NT-proBNP in troponin T-negative patients
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: Clinical stabilization without refractory ischemia
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: Lack of rapid decline in NT-proBNP levels (< or =250 ng/L)
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: Rise in NT-proBNP levels over 72 hours to >250 ng/L
Number of subjects: 1791
Study: 11731689

Group type: EXPERIMENTAL
Intervention: 2 hours bedrest
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: 4 hours bedrest
Number of subjects: 354

Group type: COMPARATOR
Intervention: 6 hours bedrest
Number of subjects: 354
Study: 9231658

Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycemia of 3.9 mmol/l
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycemia of 3.3 mmol/l
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycemia of 2.9 mmol/l
Number of subjects: 8
Study: 8029784

Group type: EXPERIMENTAL
Intervention: Melipramine (3 x 2 coated tablet) given in 60‐mg daily doses for 2 and 4 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Melipramine (3 x 2 coated tablet) given in 60‐mg daily doses
Number of subjects: 50
Study: 3323258

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg at bedtime for four days prior to chloroquine administration)
Number of subjects: 10
Study: 29402789

Group type: EXPERIMENTAL
Intervention: Hyoscine N-Butylbromide (20 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium Chloride (0.9%)
Number of subjects: 60
Study: 26797664

Group type: EXPERIMENTAL
Intervention: Self-administered computer therapy for apraxia of speech
Number of subjects: 50

Group type: COMPARATOR
Intervention: Visuospatial sham program
Number of subjects: 50
Study: 24400719

Group type: COMPARATOR
Intervention: Monofocal aspheric lens ZA9003 (control group)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Hybrid diffractive MIOLs (ZMA00)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Hybrid spherical SN60D3
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Hybrid aspheric SN6AD1
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Refractive spherical NXG1
Number of subjects: 143
Study: 22529257

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT) with fluorouracil 800 mg/m(2)/d IV infusion on days 1-4 and 29-32, and cisplatin 80 mg/m(2) IV on days 1 and 29, followed by concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and standard-dose boost (SD) of 15 Gy.
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT) with fluorouracil and cisplatin, followed by concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and high-dose boost (HD) of 20-25 Gy.
Number of subjects: 307

Group type: COMPARATOR
Intervention: Concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and standard-dose boost (SD) of 15 Gy (reference arm).
Number of subjects: 307

Group type: COMPARATOR
Intervention: Concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and high-dose boost (HD) of 20-25 Gy.
Number of subjects: 307

Group type: COMPARATOR
Intervention: Induction chemotherapy (ICT) effect comparison between groups A and B versus C and D.
Number of subjects: 307

Group type: COMPARATOR
Intervention: Radiation dose effect comparison between groups A and C versus B and D.
Number of subjects: 307
Study: 20534421

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEpo) - 3 consecutive intravenous doses (24,000 IU)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no erythropoietin treatment)
Number of subjects: 20
Study: 17313499

Group type: COMPARATOR
Intervention: Standard triple eradication therapy (esomeprazole, clarithromycin, amoxicillin)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Modified eradication therapy (standard triple therapy plus bovine lactoferrin and probiotics)
Number of subjects: 206
Study: 15252435

Group type: EXPERIMENTAL
Intervention: Educational program for homecare nurses (Power Over Pain)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 202
Study: 11287377

Group type: EXPERIMENTAL
Intervention: Walking exercise (gait)
Number of subjects: 13
Study: 9565410

Group type: EXPERIMENTAL
Intervention: Interactive seminar for physicians
Number of subjects: 637

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 637
Study: 3069881

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 21
Study: 29673831

Group type: EXPERIMENTAL
Intervention: Hypovitaminosis D defined as serum 25-hydroxyvitamin D concentration (25OHD) ≤30 ng/mL
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Serum 25OHD concentration
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Hypovitaminosis D ≤ 30 ng/mL
Number of subjects: 744
Study: 27083763

Group type: EXPERIMENTAL
Intervention: Zinc plus multivitamins (20 mg elemental zinc, vitamin A 1000 IU, vitamin D 200 IU, B1 10 mg, B2 3 mg, B6 1 mg, B12 10 μg, nicotinamide 40 mg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 24945737

Group type: EXPERIMENTAL
Intervention: silymarin (420 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 0
Study: 22257240

Group type: EXPERIMENTAL
Intervention: GreenLight HPS™ 120-W laser photovaporization of the prostate (PVP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 20
Study: 20739647

Group type: EXPERIMENTAL
Intervention: Sertraline (flexible-dose up to 200 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 38
Study: 18295700

Group type: EXPERIMENTAL
Intervention: Glidewire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HiWire
Number of subjects: 0
Study: 15718040

Group type: EXPERIMENTAL
Intervention: Primary fibroblast cultures from AD patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aged individuals
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AD fibroblasts
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EAAT1 parameters
Number of subjects: 10
Study: 15232334

Group type: EXPERIMENTAL
Intervention: Nalmefene 5 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Nalmefene 20 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Nalmefene 40 mg
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 11758326

Group type: EXPERIMENTAL
Intervention: Lidocaine (2% lidocaine mixed with propofol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol (1% propofol 20 ml with 2 ml of normal saline)
Number of subjects: 40
Study: 9399233

Group type: EXPERIMENTAL
Intervention: Patient-training videotape on motor fluctuations
Number of subjects: 32

Group type: COMPARATOR
Intervention: General patient educational material (control group)
Number of subjects: 32
Study: 7706597

Group type: EXPERIMENTAL
Intervention: 30 g/day sugar added to meals
Number of subjects: 19

Group type: COMPARATOR
Intervention: Diet similar to home diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Diabetic hospital dietary regimen without added sugar
Number of subjects: 19
Study: 3580232

Group type: EXPERIMENTAL
Intervention: Sodium thiosulphate 10.6‐38.5 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: No antidote (control group)
Number of subjects: 30
Study: 31686590

Group type: COMPARATOR
Intervention: Advanced statistical modeling (LASSO, ridge regression, elastic nets, support vector machines, random forests) applied to baseline prognostic factors for disability progression.
Number of subjects: 1582

Group type: COMPARATOR
Intervention: Advanced statistical modeling (various methods) for predicting disability progression.
Number of subjects: 1582

Group type: COMPARATOR
Intervention: Sensitivity analyses for different definitions of a combined endpoint.
Number of subjects: 1582
Study: 30930355

Group type: EXPERIMENTAL
Intervention: Lip trainer device (group P, n = 13)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sonic toothbrush (group S, n = 13)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (group C, n = 13)
Number of subjects: 39
Study: 29202535

Group type: EXPERIMENTAL
Intervention: Golimumab 50mg subcutaneously every 4 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Golimumab 50mg from week 24 to week 48
Number of subjects: 25
Study: 26700568

Group type: EXPERIMENTAL
Intervention: 12-week neuromuscular and quadriceps/hip strength training programme
Number of subjects: 48
Study: 23943468

Group type: EXPERIMENTAL
Intervention: Intermittent, CD4-guided antiretroviral therapy (ART)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Continuous antiretroviral therapy (ART)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 258
Study: 21707134

Group type: EXPERIMENTAL
Intervention: Attention Modification Program (AMP)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Attention Control Condition (Placebo)
Number of subjects: 112
Study: 18313033

Group type: EXPERIMENTAL
Intervention: Triple P-Positive Parenting Program
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Couples Coping Enhancement Training (CCET)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 150
Study: 16496019

Group type: EXPERIMENTAL
Intervention: Concentric Resistance Training (CRT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Eccentric Resistance Training (ERT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sedentary (SED)
Number of subjects: 29
Study: 14739727

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sotalol or Propafenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recurrent Atrial Fibrillation
Number of subjects: 0
Study: 10626595

Group type: EXPERIMENTAL
Intervention: 4 consecutive nights of exposure to power-frequency magnetic fields at occupational intensity (28.3 microtesla)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Equivalent no-exposure sham control conditions
Number of subjects: 30
Study: 9105355

Group type: EXPERIMENTAL
Intervention: Autogenous posterior pharyngeal wall augmentation using a rolled superiorly based pharyngeal myomucosal flap
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Autogenous posterior pharyngeal wall augmentation
Number of subjects: 14
Study: 8231271

Group type: EXPERIMENTAL
Intervention: Pneumatic dilation with a 30‐ or 35‐mm balloon dilator, one or two balloon inflations, and 20, 40, or 60 seconds per balloon inflation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pneumatic dilation
Number of subjects: 14
Study: 3991280

Group type: EXPERIMENTAL
Intervention: Furosemide, 2 mg/kg orally at diagnosis followed by 1 mg/kg 12 hours later if symptoms persisted
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 50
Study: 31362877

Group type: EXPERIMENTAL
Intervention: ApoE4+ with poor metabolic phenotype
Number of subjects: 497

Group type: COMPARATOR
Intervention: ApoE4- healthy phenotype
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: ApoE4+ poor metabolic phenotype
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: ApoE4+ women
Number of subjects: 497

Group type: COMPARATOR
Intervention: ApoE4- women
Number of subjects: 497
Study: 28558139

Group type: EXPERIMENTAL
Intervention: Surfactant solution
Number of subjects: 33

Group type: COMPARATOR
Intervention: Buffered saline
Number of subjects: 33
Study: 26055735

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Sulfadoxine-Pyrimethamine (SP)
Number of subjects: 1601
Study: 24267864

Group type: EXPERIMENTAL
Intervention: Treatment with levothyroxine (n=45; 61.6%)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Untreated women with AITD and/or subclinical hypothyroidism (n=38; 14.7%)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Euthyroid women without signs of AITD (Control group, n=147; 57.0%)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Treatment with levothyroxine
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Cost analysis
Number of subjects: 258
Study: 21878104

Group type: EXPERIMENTAL
Intervention: DAFNE program
Number of subjects: 40
Study: 19726314

Group type: EXPERIMENTAL
Intervention: Tiopronin enteric capsules (200 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Tiopronin tablets (200 mg)
Number of subjects: 9
Study: 17416857

Group type: COMPARATOR
Intervention: Weekly docetaxel (wD)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Docetaxel once every 3 weeks (3wD)
Number of subjects: 865
Study: 15108296

Group type: EXPERIMENTAL
Intervention: [H2O]-PET
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LORETA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statistical analysis
Number of subjects: 0
Study: 11877068

Group type: EXPERIMENTAL
Intervention: SIIST with HGFs
Number of subjects: 73

Group type: COMPARATOR
Intervention: SIIST alone
Number of subjects: 73
Study: 9626635

Group type: EXPERIMENTAL
Intervention: Oral risedronate, 30 mg/day for 84 days
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Oral risedronate, 30 mg/day for 84 days (repeated administration)
Number of subjects: 162
Study: 7882703

Group type: EXPERIMENTAL
Intervention: Sustained-release ibuprofen (1600 mg taken in the evening)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (substituted for a single dose of active treatment)
Number of subjects: 24
Study: 2979246

Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg o.m.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 7
Study: 31621186

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) system
Number of subjects: 38
Study: 29669442

Group type: EXPERIMENTAL
Intervention: Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms (TIME)
Number of subjects: 32
Study: 28095101

Group type: EXPERIMENTAL
Intervention: Axi‐NRT with VF
Number of subjects: 20

Group type: COMPARATOR
Intervention: Axi‐NRT without VF
Number of subjects: 20
Study: 24872078

Group type: EXPERIMENTAL
Intervention: LSVT-BIG
Number of subjects: 42

Group type: COMPARATOR
Intervention: AOT-SP
Number of subjects: 42
Study: 23577799

Group type: EXPERIMENTAL
Intervention: Flaxseed lignan (543 mg/day in BeneFlax)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 21323532

Group type: EXPERIMENTAL
Intervention: Cellular phone reminder system (ARemind) - personalized text messages daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Beeper (BP) - reminder beep at the time of dosing
Number of subjects: 23
Study: 19175889

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS) 110 microg once daily (QD)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 17445806

Group type: EXPERIMENTAL
Intervention: 10,000 IU hCG
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 5,000 IU hCG
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2,500 IU hCG
Number of subjects: 80
Study: 14997197

Group type: EXPERIMENTAL
Intervention: 3 g PSK plus 300 mg UFT orally each day for 2 years
Number of subjects: 205

Group type: COMPARATOR
Intervention: 300 mg UFT alone orally each day for 2 years
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 3 g PSK plus 300 mg UFT in stage III patients
Number of subjects: 205

Group type: COMPARATOR
Intervention: 300 mg UFT alone in stage III patients
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 3 g PSK plus 300 mg UFT
Number of subjects: 205
Study: 14551553

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12578082

Group type: EXPERIMENTAL
Intervention: Maintaining a constant preload
Number of subjects: 14

Group type: COMPARATOR
Intervention: Maintaining a constant degree of thumb abduction
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Corrected preload
Number of subjects: 14
Study: 7780046

Group type: EXPERIMENTAL
Intervention: Stavudine 5 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Stavudine 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stavudine 20 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg
Number of subjects: 16
Study: 2083186

Group type: EXPERIMENTAL
Intervention: iproplatin (240 mg/m2)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: cisplatin (100 mg/m2)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: carboplatin (300 mg/m2)
Number of subjects: 88
Study: 40440

Group type: EXPERIMENTAL
Intervention: 50 g/day of lecithin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31526123

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1382

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: Complex AAA
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: Noncomplex AAA
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: No AAA
Number of subjects: 1382
Study: 28260458

Group type: EXPERIMENTAL
Intervention: 450 mg/d valganciclovir
Number of subjects: 201

Group type: COMPARATOR
Intervention: 900 mg/d valganciclovir
Number of subjects: 201
Study: 27071541

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 8229
Study: 24727123

Group type: EXPERIMENTAL
Intervention: Simeprevir 100mg once-daily with peginterferon α‐2a/ribavirin for 12 weeks then response-guided therapy with peginterferon α‐2a/ribavirin for 12 or 36 weeks
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo with peginterferon α‐2a/ribavirin for 12 weeks then peginterferon α‐2a/ribavirin for 36 weeks
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Simeprevir 100mg once-daily with peginterferon α‐2a/ribavirin
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo with peginterferon α‐2a/ribavirin
Number of subjects: 183
Study: 22311997

Group type: EXPERIMENTAL
Intervention: Simulated ostracism (ostracized condition)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Inclusion/control condition
Number of subjects: 19
Study: 18626666

Group type: EXPERIMENTAL
Intervention: Problem-focused psychosocial intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study: 18251154

Group type: EXPERIMENTAL
Intervention: Triple‐plus‐probiotics group (1 week of PPI-based triple therapy + 8 weeks of probiotics)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Triple‐only group (1 week of PPI-based triple therapy without probiotics)
Number of subjects: 352
Study: 16340102

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) targeting either the globus pallidum internus (GPi) or subthalamic nucleus (STN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation (DBS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rehabilitation training using external visual or auditory cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of deep brain stimulation, pharmacotherapy, and rehabilitation training
Number of subjects: 0